UTL-5g

UTL-5g

• CAS Number: 646530-37-2
• UNSPSC Description: UTL-5g (GBL-5g), an anti-inflammatory TNF-α inhibitor, has chemoprotective and liver radioprotective effects. UTL-5g lowers hepatotoxicity, nephrotoxicity, and myelotoxicity induced by Cisplatin through TNF-α inhibition among other factors[1][2].
• Target Antigen: TNF Receptor
• Type: Reference compound
• Related Pathways: Apoptosis
• Field of Research: Inflammation/Immunology
• Assay Protocol: https://www.medchemexpress.com/utl-5g.html
• Purity: 99.92
• Solubility: DMSO : 100 mg/mL (ultrasonic)
• Smiles: O=C(C1=NOC(C)=C1)NC2=CC=C(Cl)C=C2Cl
• Molecular Weight: 271.10
• References & Citations: [1]Stephen Brown, et al. UTL-5g Lowers Levels of TGF-β and TNF-α Elevated by Lung Irradiation|[2]Carruthers NJ, et al. Phosphoproteome and transcription factor activity profiling identify actions of the anti-inflammatory agent UTL-5g in LPS stimulated RAW 264.7 cells including disrupting actin remodeling and STAT-3 activation. Eur J Pharmacol. 2017;811:66-73.|[3]Shaw J, et al. The small-molecule TNF-α inhibitor, UTL-5g, delays deaths and increases survival rates for mice treated with high doses of cisplatin. Cancer Chemother Pharmacol. 2013;72(3):703-707.
• Shipping Conditions: Room Temperature
• Storage Conditions: -20°C, 3 years; 4°C, 2 years (Powder)
• Clinical Information: No Development Reported